OPKO Offers Additional Data on RAYALDEE at National Kidney Foundation Spring Clinical Meetings

OPKO Health, Inc.

disclosed that additional data on RAYALDEE would be highlighted later on Thursday in a poster presentation at the National Kidney Foundation Spring Clinical Meetings, underway in Boston. According to the company, the drug was meant as a treatment for secondary hyperparathyroidism (SHPT). The pharmaceutical firm said that the data showed that plasma levels of intact parathyroid hormone (iPTH) continued to fall as serum levels of 25-hydroxyvitamin D (25D) increased above 30 ng/mL, a level considered sufficient for CKD patients in published clinical practice guidelines. The company added that these data suggested that patients with stage 3 or 4 CKD require higher levels of serum 25D than previously thought to control elevated iPTH. OPKO said that its poster presentation entitled "Modified-release Calcifediol Treatment of SHPT Indicates That Higher Than Expected Serum 25D Levels May Be Required in Subjects With CKD," would be presented by senior author Stuart Sprague, DO, Chief, Division of Nephrology and Hypertension, NorthShore University Health System - University of Chicago, Pritzker School of Medicine. On Thursday, the stock traded 0.28%.